Loading stock data…
Cytokinetics, Incorporated (CYTK)
$75.35+2.63 (+3.62%)
Market ClosedLast close Sep 8
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cytokinetics, Incorporated in the Healthcare sector is trading at $75.35 with a market capitalization of $10.5B. Wall Street consensus targets $109.90 (20 analysts), implying a +45.9% move over the next 12 months. The stock is currently 15% below its 52-week high of $88.31, remaining 7.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +45.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | $66.77M↑ | $1.94M↓ | $17.75M↓ | $19.36M↓ | $28.62M |
| Gross Profit | $64.35M↑ | -$97.30M↓ | -$86.64M↓ | $16.80M↓ | $23.03M |
| Operating Income | -$111.51M↑ | -$166.75M↑ | -$178.37M↑ | -$183.62M↓ | -$179.17M |
| Net Income | -$134.37M↑ | -$306.18M↓ | -$183.03M↑ | -$206.03M↓ | -$198.76M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.48B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
515.31%
Volume
Today's trading volume
1.92M
Recent News
Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?
Cytokinetics, Incorporated (NASDAQ:CYTK) has reported detailed late-stage results that could support an expansion of aficamten into a form of genetic heart disease that currently does not have any approved treatments. Aficamten is already approved under the brand name Myqorzo for obstructive hypertrophic cardiomyopathy, or oHCM, in which thickened heart muscle restricts blood flow. Cytokinetics (NASDAQ:CYTK) […]
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
Cytokinetics (CYTK) Presents New Phase 3 Data, Is It Still 34% Undervalued?
Cytokinetics (CYTK) is back in focus after presenting new Phase 3 data for aficamten in hypertrophic cardiomyopathy at the European Society of Cardiology Congress 2026, alongside plans for a supplemental FDA filing. Cytokinetics shares have been under pressure in recent weeks, with the 7 day share price return down 8.46% and the 30 day share price return down 8.06%, even as the stock posts a year to date share price gain of 14.87% and a 1 year total shareholder return of 42.91%. This suggests...
Cytokinetics (CYTK) Reaches A Phase 3 First In Non Obstructive HCM
Cytokinetics (NasdaqGS: CYTK) reports positive Phase 3 results for aficamten (MYQORZO) in patients with symptomatic non-obstructive hypertrophic cardiomyopathy. The trial is described as the first successful clinical study in this indication, with results presented at a major cardiology conference and published in leading medical journals. Cytokinetics plans to submit a supplemental New Drug Application seeking an expanded label for aficamten in non-obstructive hypertrophic...
Jefferies starts biopharma firm Braveheart at Buy after IPO
Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.